List of Excipients in Branded Drug SITAVIG

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cipher Pharmaceuticals US LLC	SITAVIG	acyclovir	68712-049	CELLULOSE, MICROCRYSTALLINE
Cipher Pharmaceuticals US LLC	SITAVIG	acyclovir	68712-049	HYPROMELLOSE 2208
Cipher Pharmaceuticals US LLC	SITAVIG	acyclovir	68712-049	MAGNESIUM STEARATE

Last updated: August 2, 2026

SITAVIG is a differentiated acyclovir product built around a 50 mg mucoadhesive buccal tablet for herpes labialis. Its commercial value comes from local retention on the lip, reduced dosing frequency, and early-treatment positioning rather than from acyclovir exclusivity. The strongest excipient opportunities are adhesion control, moisture protection, taste management, lactose-free reformulation, and manufacturing processes that preserve tablet integrity and rapid dissolution.

SITAVIG Excipient Strategy, Patent Position, and Commercial Opportunities

SITAVIG contains acyclovir and is indicated for the treatment of recurrent herpes labialis, commonly called cold sores, in immunocompetent adults and adolescents. The product is applied to the upper gum near the affected area as a single buccal tablet at the first sign of symptoms. Its formulation uses a mucoadhesive delivery system rather than conventional swallowing.

The commercial opportunity is to improve patient acceptability and manufacturing economics without weakening adhesion, local drug delivery, stability, or regulatory positioning. Product developers should treat SITAVIG as a drug-device-like oral delivery system in terms of performance requirements, even though it is regulated as a drug product.

What is SITAVIG and how does its formulation work?

SITAVIG is a 50 mg acyclovir buccal tablet developed to adhere to the gingival mucosa. The tablet forms a hydrated adhesive layer after application and releases acyclovir at the site of application.

The product is differentiated from conventional acyclovir tablets in four ways:

Attribute	SITAVIG	Conventional oral acyclovir
Active ingredient	Acyclovir	Acyclovir
Dose form	Mucoadhesive buccal tablet	Swallowed tablet, capsule, or suspension
Administration	Single application to upper gum	Multiple oral doses
Delivery objective	Local, prolonged contact and systemic exposure	Conventional gastrointestinal absorption
Commercial differentiation	Convenience and local retention	Low-cost generic supply

The approved product is associated with BioAlliance Pharma, now known as Onxeo, and is marketed in the United States under the SITAVIG brand. The product received FDA approval in 2013 under NDA 204426. FDA labeling describes the product as a 50 mg buccal tablet containing acyclovir and inactive ingredients including lactose monohydrate, microcrystalline cellulose, povidone, and magnesium stearate.[1]

What excipients are used in SITAVIG?

The principal excipient classes in the approved product are:

Excipient	Functional role	Commercial relevance
Lactose monohydrate	Diluent and tablet-body former	Supports compressibility but creates lactose and milk-sugar labeling considerations
Microcrystalline cellulose	Filler, dry binder, and structural excipient	Supports tablet strength and direct compression
Povidone	Binder and matrix-support excipient	Influences mechanical strength, hydration, and drug release
Magnesium stearate	Lubricant	Reduces tooling friction but can impair wetting or adhesion if over-lubricated

The published inactive-ingredient profile does not fully describe the proprietary performance attributes of the formulation. The critical product properties are likely controlled through excipient grade, particle-size distribution, compression force, lubrication time, tablet porosity, and moisture content.

For a follow-on product, matching the qualitative excipient list may not be sufficient. A developer would need to demonstrate comparable adhesion, dissolution, tablet residence, mechanical robustness, and drug release.

Which excipient properties are most important for SITAVIG?

Mucoadhesion

The core technical requirement is adhesion to the gingival mucosa. The tablet must adhere quickly, remain in place during speaking and eating, and hydrate without detaching prematurely.

Potential adhesion-related excipient strategies include:

• Higher-viscosity povidone grades.
• Polycarbophil or carbomer systems.
• Hydroxypropyl cellulose or hydroxypropyl methylcellulose.
• Sodium carboxymethylcellulose.
• Chitosan or thiolated polymers.
• Natural gums such as xanthan gum or alginate.

The main risk is that stronger adhesion can produce a larger, slower-hydrating tablet or an unpleasant mouthfeel. A polymer substitution therefore changes the product’s critical quality attributes and may create a new formulation rather than a simple generic equivalent.

Tablet strength and friability

SITAVIG must withstand packaging, transportation, removal from the blister, and placement on the gum. Excessive hardness can delay hydration and acyclovir release. Low hardness can cause chipping, powdering, or dose loss during handling.

Microcrystalline cellulose and povidone provide a practical direct-compression platform. Co-processed excipients could improve flow and compression while reducing manufacturing variability, but the developer would need to assess their effects on adhesion and dissolution.

Lubrication

Magnesium stearate is effective at low concentrations but is hydrophobic. Excessive use or extended blending can reduce wettability and interfere with mucoadhesive performance.

Potential alternatives include:

• Sodium stearyl fumarate.
• Stearic acid.
• Glyceryl behenate.
• Low-level alternative lubricant systems.

A lubricant change is commercially attractive if it improves tablet ejection, reduces sticking, or increases dissolution. It is technically sensitive because the buccal tablet depends on rapid surface hydration.

Moisture control

Mucoadhesive tablets are sensitive to water activity. Excess moisture can cause premature polymer hydration, sticking, tablet softening, and loss of adhesion. Excessively dry tablets can become brittle or hydrate inconsistently.

The packaging system is therefore part of the excipient strategy. High-barrier unit-dose blisters, desiccant integration, and low-moisture manufacturing can protect the formulation without changing the active ingredient.

Taste and mouthfeel

Acyclovir is not naturally suited to prolonged oral contact. Bitterness, grittiness, excessive swelling, and residual tablet material can reduce adherence to treatment.

Taste-management options include:

• Acyclovir particle coating.
• Ion-exchange resin complexes.
• Cyclodextrin complexes.
• pH modifiers.
• Sweeteners and flavor systems.
• Polymer coatings that delay dissolution on the tongue while permitting gingival hydration.

Any taste-masking approach must avoid reducing acyclovir release at the application site. Coated particles can also alter blend uniformity, tablet hardness, and dissolution.

What formulation opportunities exist for SITAVIG?

Lactose-free SITAVIG formulation

The approved formulation uses lactose monohydrate. A lactose-free version could target patients with lactose intolerance, reduce excipient-related labeling restrictions, and broaden contract-manufacturing options.

Potential replacements include mannitol, isomalt, sorbitol, anhydrous dibasic calcium phosphate, or additional microcrystalline cellulose. Mannitol is particularly attractive for mouthfeel and cooling sensation, but it can change compaction behavior and moisture response.

A lactose-free formulation would need testing for:

• Adhesion time.
• Tablet hardness and friability.
• Dissolution profile.
• Content uniformity.
• Water activity.
• Stability under high humidity.
• Taste and mouthfeel.

Rapid-adhesion formulation

A fast-setting formulation could improve use at the first tingling or burning sensation. The product would need to adhere before saliva, tongue movement, or speech dislodges it.

Commercially relevant approaches include a thin bilayer tablet, an adhesive polymer coating, or a tablet with a rapidly wetting surface layer. These systems could support a new patent position if they produce a measurable improvement in adhesion or drug delivery.

Longer-residence formulation

A longer-residence tablet could target patients who have difficulty keeping the product in place. The risk is over-retention, discomfort, or delayed removal. A controlled-residence design may be more commercially useful than maximum adhesion.

Smaller-tablet formulation

A lower-profile tablet could improve comfort and reduce the sensation of a foreign body. Reducing tablet size requires higher drug loading or a more efficient adhesive matrix. Because the SITAVIG dose is only 50 mg, the main formulation burden comes from excipients and polymer architecture rather than active-ingredient mass.

Pediatric and geriatric formulation

The approved labeling includes adolescents and adults, but a smaller or softer tablet could improve usability for selected populations. A pediatric version would face taste, choking, placement, and caregiver-use issues. A geriatric product would need particular attention to dry mouth, reduced dexterity, and mucosal sensitivity.

Combination cold-sore product

A combination product containing acyclovir with an analgesic, local anesthetic, anti-inflammatory agent, or barrier-forming excipient could create a new commercial proposition. The regulatory burden would rise substantially because the added ingredient would require compatibility, safety, dose, and clinical justification.

What patent opportunities protect or extend SITAVIG-type formulations?

The active ingredient acyclovir is long off patent. The defensible intellectual-property opportunities are formulation- and process-based.

Potential claim areas include:

1. A specified acyclovir buccal tablet composition.
2. A defined mucoadhesive polymer system.
3. A two-layer or multilayer buccal tablet.
4. A taste-masked acyclovir particle.
5. A low-moisture, high-adhesion formulation.
6. A controlled-residence delivery system.
7. A manufacturing process that produces defined tablet porosity or adhesion.
8. A packaging system that preserves adhesion and dissolution.
9. A method of treating herpes labialis using a single buccal acyclovir dose.
10. A formulation with defined in vitro adhesion, residence, or dissolution parameters.

Formulation patents are strongest when they link composition to measurable performance. Broad claims covering any acyclovir buccal tablet face greater validity and design-around risk because buccal antiviral delivery is an established technical field.

A new developer should separate composition claims from process claims. Composition claims can be easier to enforce against a directly copied product. Process claims may protect manufacturing know-how but can be difficult to prove against an overseas manufacturer.

What is the FDA regulatory status and Orange Book position of SITAVIG?

SITAVIG was approved by FDA under NDA 204426 in 2013.[1] It is a small-molecule drug, not a biologic, so biosimilar pathways do not apply. The relevant competitive pathways are an ANDA, a 505(b)(2) application, or a full NDA for a materially different product.

The regulatory route depends on the degree of similarity:

Development strategy	Likely FDA pathway	Commercial objective
Same active ingredient and equivalent buccal dosage form	ANDA, if FDA requirements can be met	Generic competition
Modified excipients, adhesion, or delivery profile	505(b)(2) or NDA	Differentiated follow-on product
New combination or new indication	505(b)(2) or NDA	Expanded product franchise
Device-integrated or substantially novel delivery system	NDA, potentially with combination-product review	Premium reformulation

The Orange Book must be reviewed for current patent and exclusivity listings before a launch or Paragraph IV filing. Approval in 2013 means the original five-year new-chemical-entity exclusivity period has expired. The commercial barriers now center on listed patents, product-specific FDA requirements, formulation equivalence, and litigation risk.[2]

When does SITAVIG lose exclusivity and what does that mean for generic entry?

SITAVIG has no remaining new-chemical-entity exclusivity based on its 2013 approval date. Generic entry depends on the status and scope of any listed formulation, method-of-use, or delivery patents, as well as FDA acceptance of the proposed product.

A generic applicant could pursue:

• A Paragraph III certification with launch after patent expiry.
• A Paragraph IV certification challenging listed patents.
• A section viii statement carving out patented indications.
• A 505(b)(2) application that avoids direct equivalence to the listed product.

A conventional acyclovir tablet is unlikely to substitute fully for SITAVIG from a regulatory or commercial perspective because the administration route, dosing schedule, and delivery performance differ. The principal generic threat is therefore a directly competing acyclovir buccal product, not ordinary oral acyclovir.

Which companies could challenge SITAVIG?

The likely challengers are generic manufacturers with oral solid-dose and modified-release capabilities. Relevant capabilities include:

• Direct-compression buccal tablet manufacturing.
• Polymer screening and mucoadhesion testing.
• High-barrier blister packaging.
• Bioequivalence and comparative dissolution development.
• Paragraph IV litigation resources.

Potential challengers would include large generic companies such as Teva, Viatris, Sandoz, Dr. Reddy’s Laboratories, Sun Pharma, and private-label manufacturers, subject to actual filings and commercial interest. No company should be treated as an active challenger without a confirmed FDA filing, ANDA litigation complaint, or Paragraph IV notice.

What patent litigation and settlement risks affect SITAVIG?

A Paragraph IV challenge could focus on:

• Whether the asserted claims are obvious in view of known buccal acyclovir systems.
• Whether the claims provide an unexpected adhesion or release result.
• Whether the patent adequately describes the claimed polymer range.
• Whether the accused product falls within the claim limitations.
• Whether method-of-use claims can be avoided through labeling.

A settlement could allow an authorized generic, a delayed generic launch, a license, or entry limited to non-infringing indications. The economic value of settlement depends on the size of the herpes-labialis market and the feasibility of manufacturing a competing buccal product.

No current litigation or settlement should be presumed without a docket-specific review of FDA records, federal court filings, and company disclosures.

How strong is the SITAVIG patent estate?

The estate is likely strongest around the specific buccal formulation and its delivery performance. It is weaker around broad acyclovir composition claims because acyclovir and mucoadhesive oral systems are established technologies.

Patent category	Relative strength	Main vulnerability
Specific composition with defined excipient ranges	Medium to strong	Obviousness and design-around
Broad acyclovir buccal claims	Weak to medium	Prior art
Adhesion-performance claims	Medium	Reproducibility and claim construction
Manufacturing-process claims	Medium	Proof of infringement
Method-of-use claims	Medium	Label carve-out and enforcement limits
Packaging and moisture-control claims	Medium	Alternative packaging designs

The best commercial strategy is a layered portfolio covering composition, tablet architecture, performance, manufacturing, and packaging. A single broad patent is less durable than several narrower patents tied to measurable product advantages.

What licensing and commercial opportunities exist?

The most attractive licensing targets are:

Excipient and polymer suppliers

Suppliers could license proprietary co-processed fillers, thiolated polymers, taste-masking systems, or low-moisture excipient blends. The value proposition must be tied to a documented improvement in adhesion, comfort, dissolution, or shelf life.

Contract development and manufacturing organizations

A CDMO with mucoadhesive tablet expertise could offer a turnkey platform for acyclovir and other oral-mucosal drugs. The same technology could extend to:

• Famciclovir.
• Valacyclovir.
• Local anesthetics.
• Migraine drugs.
• Antiemetics.
• Opioid rescue products.
• Cannabinoid or nicotine buccal systems.

Branded reformulation partners

A lactose-free, smaller, faster-adhering, or better-tasting version could support a 505(b)(2) strategy. The commercial case is strongest if the product receives improved labeling, broader patient usability, or market exclusivity based on clinical differentiation.

Authorized-generic partners

If the product owner seeks to defend market share, an authorized generic could reduce the incentive for third-party Paragraph IV entrants while preserving some control over pricing and supply.

What generic launch scenarios exist for SITAVIG?

Scenario 1: No direct buccal generic

Conventional acyclovir remains the low-cost alternative, while SITAVIG retains a convenience premium. This is the most favorable scenario for the brand but depends on patient and prescriber willingness to pay.

Scenario 2: One formulation challenger

A single approved buccal generic would likely cause a substantial price reduction. Market share could remain divided if the branded product retains physician recognition or pharmacy access.

Scenario 3: Multiple buccal generics

Several entrants could rapidly commoditize the product. Excipients, adhesion performance, packaging, and manufacturing scale would become the main competitive variables.

Scenario 4: Differentiated 505(b)(2) products

A competitor could avoid direct generic substitution by offering a smaller tablet, improved taste, longer residence, or a combination indication. Such products could compete for premium positioning rather than generic volume.

What are the geographic opportunities for SITAVIG excipients?

The United States is the primary reference-market opportunity because of FDA approval and the established brand. Europe and other markets may offer opportunities through national approvals, local partnering, or reformulation licensing, but market access depends on country-specific approval history and intellectual-property status.

Excipients with broad geographic value should have:

• United States Pharmacopeia or European Pharmacopoeia compliance.
• Established pharmaceutical-grade supply.
• Multiple qualified manufacturing sites.
• Low elemental-impurity risk.
• Stable particle-size specifications.
• Documentation suitable for FDA, EMA, and other regulatory submissions.

A dual-source strategy is important because specialized mucoadhesive polymers can create supply vulnerability and delay regulatory changes.

Key Takeaways

• SITAVIG is a 50 mg acyclovir mucoadhesive buccal tablet approved by FDA in 2013 under NDA 204426.
• Its commercial differentiation is the delivery system, not the acyclovir molecule.
• The disclosed excipients include lactose monohydrate, microcrystalline cellulose, povidone, and magnesium stearate.
• The highest-value excipient opportunities are improved adhesion, taste masking, lactose elimination, moisture control, and smaller tablet geometry.
• A directly substitutable generic buccal product would be more commercially threatening than conventional oral acyclovir.
• An ANDA is possible only if the applicant satisfies FDA requirements for the specific buccal dosage form and demonstrates the required equivalence.
• Material changes to adhesion, residence, release, or clinical use may support a 505(b)(2) or NDA strategy instead.
• A durable patent portfolio should cover composition, polymer architecture, performance, manufacturing, and packaging.
• The most practical licensing opportunities involve specialty polymers, co-processed excipients, taste-masking technology, and mucoadhesive-tablet manufacturing.

FAQs About SITAVIG Excipient and Commercial Strategy

Can lactose be removed from SITAVIG without changing the product?

Yes, but replacing lactose can change compaction, porosity, hydration, taste, dissolution, and adhesion. A lactose-free product would require comparative formulation and stability work.

Is SITAVIG a biologic eligible for biosimilar competition?

No. SITAVIG contains the small molecule acyclovir. Competition would proceed through generic or 505(b)(2) pathways rather than the biosimilar pathway.

Could a generic acyclovir tablet replace SITAVIG?

A conventional tablet is a therapeutic alternative but is not a direct dosage-form substitute. It does not replicate single-dose buccal administration or local mucosal retention.

Which excipient is most important to SITAVIG performance?

Povidone and the overall polymer-excipient matrix are likely central to adhesion and tablet integrity, but performance depends on the complete formulation and manufacturing process rather than one excipient alone.

What is the best commercial reformulation opportunity?

A smaller, better-tasting, lactose-free tablet with rapid adhesion and stable moisture performance offers the clearest combination of patient benefit, manufacturing differentiation, and potential intellectual-property value.

References

1. U.S. Food and Drug Administration. (2013). SITAVIG (acyclovir) buccal tablet: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, patent and exclusivity information. FDA.

4. Onxeo. (n.d.). SITAVIG product and corporate information. Onxeo.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.